Gait Patterns After Intraarticular Treatment of Patients With Osteoarthritis of the Knee
Condition: Osteoarthritis
MeSH terms: Osteoarthritis
Study type: Interventional
Phase: Phase 4

Summary: 
      The aim of this study was to analyse the difference of the functional and clinical outcome
      after intraarticular treatment of patients with osteoarthritis of the knee with a single
      injection of hyaluronan (HA) or Triamcinolone (TA) with respect to the quality of life during
      the study period.
    

Detailed description: 
      Osteoarthritis (OA) is the most common chronic joint disease of the aging patient. The
      primarily affected joints are the knee and hip. The progress of the disease has an important
      influence on the patient´s life, including functional and social activities, body image and
      emotional well being. Furthermore, socioeconomic aspects play an eminent role in the
      treatment of osteoarthritis in joints.

      In non-operative treatment, pain reduction and improved function are the primary goals. It is
      important to distinguish between systemic and local therapeutic options. In the systemic
      treatment, palliation of pain can be achieved by simple analgetics, non- steroidal
      anti-inflammatory drugs and opioids. Local therapy can selectively treat the symptomatic
      joint. Intraarticular application of different drugs by injection can be performed.
      Glucocorticoids are the most commonly used intraarticular agents, which reduce pain and
      improve function and well being. In recent years, the intraarticular use of different
      hyaluronan (HA) products became more widely accepted. Hyaluronan is a physiological component
      of the synovial fluid and cartilage matrix. It is responsible for the viscoelastic properties
      of the synovial fluid. In osteoarthrotic joints, the molecular weight and the concentration
      of endogenous HA are decreased compared with healthy joints. This implies a reduction of the
      viscoelasticity of the synovial fluid. In order to restore this viscoelasticity, augment the
      flow of the synovial fluid, normalise the synthesis and inhibit the degradation of endogenous
      hyaluronan, an application of exogenous HA can be performed. The therapeutic effects and the
      safety of intraarticular application of HA in the treatment of OA in the knee have been
      demonstrated in several clinical trials. Until now there are only three studies that
      objectively analysed few aspects of the functional outcome after treatment with HA.
    

Intervention name(s): hyaluronic acid; triamcinolone
Intervention type(s): Drug; Drug
Intervention description(s): one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack; one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)
antiinflammatory intervention
Other intervention name(s): 20 mg/ml non-animal stabilized hyaluronic acid (NASHA); triamcinolone acetonide, 10mg/ml
Intervention MeSH terms: Triamcinolone; Triamcinolone Acetonide; Triamcinolone hexacetonide; Hyaluronic Acid; Triamcinolone diacetate
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Keywords: Osteoarthritis; Knee; Hyaluronan; Gait Analysis